OakChart

Stevanato Group Spa

STVNHealthcare·Medical Instruments & Supplies·Italy·Mid·NYSE·Nov 11 • 2:28 PM ET

13.99+0.47 (3.44%)
2026-11-11 20:28 CET
Market cap
3,693.74 USD m
Revenue, TTM
1,449.65 USD m
Net income, TTM
163.03 USD m
Free cash flow, TTM
14.42 USD m
EPS diluted, TTM
0.60
P/E
23.44
Compare

Price

STVN against its 20, 50 and 200-day averages
2050200missearnings
15.0020.002.4M4.8MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26STVNclose 14.0020-day 17.3950-day 19.38200-day 17.9314.0052w low

45.0% under the 52-week high of 25.45 on 11 Nov 2025. 52-week low 12.05 on 4 Nov 2026. Last 15 sessions, 72.6% high to low

Profile

STVN
52-week range, 14% of the way up
12.0525.45

Stevanato Group SpA engages in the provision of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It operates through the following segments: Biopharmaceutical and Diagnostic Solutions, and Engineering segments. The Biopharmaceutical and Diagnostic Solutions segment includes all the products, processes, and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. The Engineering segment deals with all the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology and diagnostic manufacturing processes. The company was founded by Giovanni Stevanato in 1949 and is headquartered in Piombino Dese, Italy.

IPOJul 16, 2021
Beta0.84
ATR, 14d1.11
Rel volume0.87
Short float1.81%
Insider own82.08%
Inst own16.61%

Snapshot

6 groups

Valuation

Index-
Market Cap3.82B
Enterprise Value4.22B
Income163.03M
Sales1.45B
Book/sh6.63
Cash/sh0.48
Dividend Est.0.04 (0.25%)
Dividend TTM0.06 (0.45%)
Dividend Ex-DateJun 11, 2026
Dividend Gr. 3/5Y0.00% -
Payout10.76%
Employees-
IPOJul 16, 2021

Ratios

P/E23.44
Forward P/E19.27
PEG1.57
P/S2.64
P/B2.11
P/C29.28
P/FCF264.96
EV/EBITDA11.46
EV/Sales2.91
Quick Ratio1.19
Current Ratio1.73
Debt/Eq0.29
LT Debt/Eq0.22
Option/ShortYes / Yes

Earnings

EPS (ttm)0.60
EPS next Y0.73
EPS next Q0.22
EPS this Y12.65%
EPS next Y6.91%
EPS next 5Y12.25%
EPS past 3/5Y0.64% 11.33%
Sales past 3/5Y9.00% 12.15%
EPS Y/Y TTM4.96%
Sales Y/Y TTM11.99%
EPS Q/Q14.12%
Sales Q/Q5.89%
EarningsNov 03 BMO
EPS/Sales Surpr.1.94% 1.51%

Ownership

Insider Own82.08%
Insider Trans-0.00%
Inst Own16.61%
Inst Trans-0.16%
ROA5.56%
ROE9.32%
ROIC7.41%
Gross Margin28.84%
Oper. Margin17.58%
Profit Margin11.25%
SMA20-19.54%
SMA50-27.77%
SMA200-21.93%
Trades-

Technical

Shs Outstand49.83M
Shs Float48.94M
Short Float1.81%
Short Ratio1.47
Short Interest0.89M
52W High25.45 -45.01%
52W Low12.05 16.14%
Volatility8.14% 5.65%
ATR (14)1.11
RSI (14)27.87
Beta0.84
Rel Volume0.87
Avg Volume602.06K
Volume408,193

Performance

Perf Week4.13%
Perf Month-27.34%
Perf Quarter-34.97%
Perf Half Y-21.64%
Perf YTD-30.44%
Perf Year-42.10%
Perf 3Y-51.08%
Perf 5Y-39.15%
Perf 10Y-
Recom1.79
Target Price19.63
Prev Close13.53
Price13.99
Change %3.44%

Analyst ratings

latest 10 of 19
DateActionAnalystRating changeTargetImplied
Nov 04, 2026DowngradeWWilliam BlairOutperform → Mkt Perform
Oct 07, 2026InitiatedDDeutsche BankHold
Sep 09, 2026InitiatedUUBSNeutral
Jun 16, 2026InitiatedTTD CowenBuy$25+78.6%
Jun 02, 2026ResumedWWolfe ResearchOutperform$21+50.1%
Dec 02, 2025ResumedMMorgan StanleyEqual-Weight$24+71.5%
Dec 13, 2024InitiatedWWolfe ResearchOutperform$28+100.1%
Dec 03, 2024ResumedMMorgan StanleyEqual-Weight$23+64.3%
Apr 22, 2024InitiatedEExane BNP ParibasOutperform
Nov 01, 2023DowngradeJJefferiesBuy → Hold$39 → $29+107.2%

Peers

Mkt cap
TickerCompanyMkt cap
WSTWest Pharmaceutical Services Inc28.84B
ATRAptargroup Inc9.07B
BDXBecton Dickinson & Co58.05B
AVTRAvantor Inc10.69B
RGENRepligen Corp11.05B
ICUIICU Medical Inc4.47B
KRMDKORU Medical Systems Inc175.22M
TMOThermo Fisher Scientific Inc266.76B
GLWCorning Inc104.72B
AMCRAmcor Plc20.53B

Insider trading

13 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
MOREL DONALD E JRDirectorNov 06 '26Buy13.0725,000326,75062,424Nov 10 04:30 PM
Stocchi MauroSee RemarksSep 28 '26Sale21.5013,649293,454400,000Sep 30 05:20 PM
Mauro StocchiOfficerSep 14 '26Proposed Sale20.2413,649276,255Sep 14 09:57 AM
Santel LucianoDirectorAug 07 '26Sale20.092,02340,6424,739Aug 10 04:15 PM
Dal Lago MarcoChief Financial OfficerAug 07 '26Sale20.094,20984,55981,144Aug 10 04:15 PM
Magistretti ElisabettaDirectorAug 07 '26Sale20.092,04541,0842,930Aug 10 04:15 PM
Dal Lago MarcoChief Financial OfficerAug 07 '26Proposed Sale20.094,20984,555Aug 07 11:56 AM
Balachandran MadhavanDirectorJun 15 '26Sale17.091,49325,51569,458Jun 26 06:18 AM
Dal Lago MarcoChief Financial OfficerJun 12 '26Option Exercise0.007,997085,353Jun 26 06:16 AM
MOREL DONALD E JRDirectorJun 15 '26Sale17.091,49325,51537,424Jun 26 06:12 AM
Stocchi MauroSee RemarksJun 09 '26Option Exercise0.006,5860413,629Jun 26 06:07 AM
Flynn KarenDirectorJun 15 '26Sale17.091,49325,5155,757Jun 26 06:05 AM
FEDERICI WILLIAM JDirectorJun 15 '26Sale17.091,49325,51526,991Jun 26 06:04 AM

Held by

AUM
TickerCompanyAUM
IBBiShares Biotechnology ETFAUM: 11.36B
NBSMNeuberger Small-Mid Cap ETFAUM: 117.34M
KOMPState Street SPDR S&P Kensho New Economies Composite ETFAUM: 2.46B
AIMSAcuitas Small Cap Active ETFAUM: 82.88M
SMLVState Street SPDR US Small Cap Low Volatility Index ETFAUM: 262.98M
SCAPInfrastructure Capital Small Cap Income ETFAUM: 17.55M
BCGDBaron Global Durable Advantage ETFAUM: 9.63M
ACSGAmerican Century Small Cap Growth Insights ETFAUM: 53.23M
TMEDT. Rowe Price Health Care ETFAUM: 38.55M
FESCFirst Eagle Small Cap Equity ETFAUM: 5.09M

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-030.1790.1760.168364.99359.5611
2026Q22026-08-040.1610.1440.098347.51340.111
2026Q12026-05-070.1290.1220.120321.41313.9610
2025Q42026-03-040.2090.1990.203402.31393.9911
2025Q32025-11-060.1610.1470.154348.55338.5810
2025Q22025-08-050.1270.1240.123324.35316.481
2025Q12025-05-080.1130.1010.102289.35281.8310
2024Q42025-03-060.2050.1910.189356.86335.510
2024Q32024-11-050.1310.1370.121302.18298.619
2024Q22024-08-060.0990.1060.081284.27274.979
2024Q12024-05-090.0860.1200.077253.63252.429
2023Q42024-03-070.1960.2070.183348.83351.449
2023Q32023-10-310.1590.1610.156287.37296.8410
2023Q22023-07-280.1550.1460.140282.23277.068
2023Q12023-05-040.1220.1310.114262.86257.298
2022Q42023-03-020.2020.1710.186310.89295.88

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY0.5220.5010.600917.95904.65
2022FY0.5960.5680.5671,0471,047
2023FY0.6320.6370.5941,1831,160
2024FY0.5180.4930.4701,1921,129
2025FY0.6270.6220.5921,3771,387
2026FY-0.679--1,423
2027FY-0.726--1,456
2028FY-0.853--1,571
2029FY-1.264--1,847
2030FY-1.440--1,999

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-041107406.48355.26415.27
2026Q4S2026-11-031106406.43354.8417.41
2026Q4S2026-10-181001416.46412.39424.51
2026Q4S2026-10-141007416.04411.97424.08
2026Q4S2026-09-081007432.76427.66440.23
2026Q4S2026-08-04907428.29423.22435.66
2026Q4S2026-07-21910430.79423.17434.54
2026Q4S2026-07-08911430.25422.64434
2026Q4S2026-06-21901431.74418.86436.16
2026Q4S2026-06-15911437.19424.15441.67
2026Q4S2026-05-29811439.09425.95443.55
2026Q4S2026-05-18811437.84424.53442.95
2026Q4S2026-05-11841443.63430.15448.8
2026Q4S2026-05-08841442.25428.81447.41

Estimate history

EPS, annual0.1660.3380.60.5670.5940.470.5780.5971
Period2019202020212022202320242025TTM
EPS, quarterly0.1210.1890.1020.1230.1540.2030.120.0980.176
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual600.521754.705997.4971033.8221173.3931194.2261338.8121449.65
Period2019202020212022202320242025TTM
Sales, quarterly305.249352.649270.058317.409354.289403.302320.062351.142375.142
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual264.699264.699264.699264.699265.467272.899273.004273.129
Period2019202020212022202320242025MRQ
Shares, quarterly272.769272.899272.899272.985273.004273.004273.004273.126273.129
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue1,449.651,338.811,194.231,173.391,033.82997.50754.71600.52
Cost of Goods Sold Incl. D&A1,031.53963.52878.29820.83709.52694.65543.39454.68
Gross Profit418.12375.29315.93352.57324.30302.85211.32145.84
Selling, General and Administrative Excl. Other163.21158.86148.63146.83141.83121.0899.5085.98
Research and Development23.5124.4930.5933.4332.5031.0416.887.72
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income254.91216.44167.30205.73182.48181.77111.8259.86
Interest Expense6.307.327.424.674.145.766.795.30
Unusual Expense15.15-11.907.70-2.69-5.593.750.770.79
Net Income Before Taxes235.34213.42173.38204.93197.21195.18109.6561.53
Income Taxes72.3255.6146.0047.4246.9037.1220.1617.92
Consolidated Net Income163.02157.81127.39157.51150.31158.7089.6043.32
Net Income From Continuing Operations163.03157.82127.40157.44150.13158.7689.5043.88
Net Income163.03157.82127.40157.44150.13158.7689.5043.88
EPS (Recurring)0.640.550.490.590.550.610.340.17
EPS (Basic, Before Extraordinaries)0.600.580.470.590.570.600.340.17
EPS (Diluted)0.600.580.470.590.570.600.340.17
EBITDA368.52315.01251.71290.58250.56247.30173.25111.59
Non-Operating Income (Expense)1.88-7.6021.201.1713.2822.925.397.76
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-0.741.591.546.471.56--
Price To Earnings Ratio22.6622.6647.1345.6831.4837.47--
Price To Sales Ratio3.954.104.956.164.605.96--
Gross Margin28.8428.0326.4630.0531.3730.3628.0024.29
Operating Margin17.5816.1714.0117.5317.6518.2214.829.97
Net Margin11.2511.7910.6713.4214.5215.9211.867.31
Shares Outstanding273.13273.00272.90265.47264.70264.70264.70264.70
Market Capitalization3,693.743,693.745,940.837,265.534,762.145,942.495,926.61-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue375.14351.14320.06403.30354.29317.41270.06352.65
Cost of Goods Sold Incl. D&A265.87251.23233.20281.24254.65231.80199.68251.19
Gross Profit109.2799.9286.86122.0799.6485.6170.38101.46
Selling, General and Administrative Excl. Other39.3639.9840.7443.1341.2039.7635.1435.96
Research and Development6.056.185.775.517.695.875.465.29
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income69.9259.9346.1278.9458.4445.8535.2565.50
Interest Expense1.591.491.361.862.071.931.493.16
Unusual Expense4.893.154.322.801.94-10.28-5.844.76
Net Income Before Taxes68.5344.3245.9176.5957.4144.3336.9568.91
Income Taxes20.3917.6313.1221.1815.2710.669.0517.39
Consolidated Net Income48.1426.6932.7955.4042.1433.6727.9151.52
Net Income From Continuing Operations48.1426.6932.7955.4142.1533.6727.9151.54
Net Income48.1426.6932.7955.4142.1533.6727.9151.54
EPS (Recurring)0.190.110.130.210.160.100.090.20
EPS (Basic, Before Extraordinaries)0.180.100.120.200.150.120.100.19
EPS (Diluted)0.180.100.120.200.150.120.100.19
EBITDA99.3688.0674.96106.1483.8870.3056.9586.51
Non-Operating Income (Expense)5.09-10.975.462.302.99-9.87-2.6511.32
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Price To Earnings Ratio22.6630.0823.5835.3748.0949.5243.6447.13
Price To Sales Ratio3.953.452.694.085.435.354.624.98
Gross Margin29.1328.4527.1430.2728.1226.9726.0628.77
Operating Margin18.6417.0714.4119.5716.4914.4513.0518.58
Net Margin12.837.6010.2513.7411.9010.6110.3314.61
Shares Outstanding273.13273.13273.00273.00273.00272.99272.90272.90
Market Capitalization3,693.744,933.183,753.805,490.737,027.156,666.925,572.605,940.83

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments153.39101.7676.89273.91498.33192.25141.74
Short Term Receivables633.58548.68577.16394.32316.62237.05211.42
Inventories318.67259.96293.21228.35169.77171.04148.38
Other Current Assets2.280.974.846.080.062.603.12
Total Current Assets1,107.92911.37952.09902.65984.78602.93504.66
Net Property, Plant & Equipment1,648.841,309.011,156.28705.12472.40414.83344.52
Total Investments and Advances7.025.846.334.932.244.305.17
Long-Term Note Receivable---0.000.517.296.62
Intangible Assets102.0086.5489.4484.7490.0399.2892.12
Deferred Tax Assets121.9998.7384.2373.8663.5455.7437.15
Other Assets0.000.000.000.000.000.000.00
Total Assets2,987.772,411.492,288.371,771.311,613.511,184.37990.25
Short Term Debt Incl. Current Port. of LT Debt142.98115.91158.0674.5849.5599.3982.97
Accounts Payable309.24239.22306.89255.26187.40145.28106.69
Income Tax Payable26.3426.3334.0244.4622.1123.406.39
Other Current Liabilities150.80112.96135.53119.30126.03118.7899.10
Total Current Liabilities629.36494.42634.50493.61385.08386.86295.15
Long Term Debt407.72328.29282.39158.39230.05359.88350.38
Provision for Risks Charges11.6810.3112.5814.8017.4641.7334.23
Deferred Tax Liabilities15.5713.0110.6322.3621.7314.2211.71
Other Liabilities177.59111.2297.0919.272.062.210.83
Total Liabilities1,241.93957.251,037.19708.43656.37804.90692.29
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00
Common Equity1,745.801,454.191,251.051,063.12957.61379.91298.01
Total Shareholders Equity1,745.801,454.191,251.051,063.12957.61379.91298.01
Accumulated Minority Interest0.040.050.13-0.23-0.47-0.43-0.06
Total Equity1,745.841,454.241,251.181,062.88957.13379.47297.96
Total Liabilities & Stockholders Equity2,987.772,411.492,288.371,771.311,613.511,184.37990.25
Book Value Per Share6.395.334.714.023.621.441.13
Tangible Book Value Per Share6.025.014.383.703.281.060.78
Price to Book Ratio2.044.036.245.046.216.46-
Return on Assets5.855.427.768.8711.358.23-
Return on Equity9.869.4213.6114.8623.7426.41-
Return on Invested Capital7.337.1510.2712.2913.3712.106.77
Quick Ratio1.251.321.041.372.121.121.21
Current Ratio1.761.841.501.832.561.561.71

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income233.49213.42173.38204.93197.21195.82109.7661.24
Depreciation112.5498.5884.4184.8468.0865.5361.4451.73
Other Funds (Non Cash)-45.47-46.27-70.46-65.23-32.97-54.54-31.57-37.37
Funds from Operations300.56265.72187.33224.54232.32206.81139.6275.60
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-2.1157.14-18.83-110.79-123.74-49.2137.82-27.95
Cash from Operating Activities298.45322.86168.50113.74108.58157.60177.4447.65
Capital Expenditures-307.96-310.40-339.19-477.78-255.52-133.78-109.44-82.72
Net Assets From Acquisitions0.000.00-0.19-4.150.000.00-0.610.00
Sale of Fixed Assets and Businesses2.992.103.400.620.151.380.020.22
Purchase or Sale of Investments4.200.280.42-4.530.0318.42-0.11-0.71
Purchase of Investments0.000.000.00-4.530.000.00-0.11-0.71
Sale Or Maturity of Investments4.200.280.420.000.0318.420.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.0030.170.000.000.000.00
Cash from Investing Activities-300.77-308.01-335.56-455.66-255.33-113.97-110.15-83.20
Cash Dividends Paid-16.89-16.63-15.64-15.45-14.19-13.24-10.15-6.91
Change in Capital Stock0.000.00183.640.000.00439.540.000.00
Repurchase of Common Pref Stock0.000.000.000.000.00-9.720.000.00
Sale of Common Pref Stock0.000.00183.640.000.00449.260.000.00
Proceedsfrom Stock Options0.000.00183.640.000.00449.260.000.00
Issuance or Reduction of Debt, Net-48.6237.19192.99-25.69-134.37-12.7459.41
Net Financing Active Other Cash Flow0.000.000.000.000.0016.970.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.00
Cash from Financing Activities1.0024.90198.19171.12-46.81301.22-29.6147.20
Exchange Rate Effect3.77-3.26-0.12-1.251.974.35-3.230.52
Net Change in Cash2.4636.4931.01-172.05-191.59349.2034.4412.16
Free Cash Flow14.4225.19-158.82-354.63-138.4330.3175.34-28.56
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Price to Free Cash Flow-641.65---348.05--
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments130.5189.91128.67153.39133.17110.54
Short Term Receivables614.96622.64585.00633.58575.65564.36
Inventories342.52353.27339.16318.67322.76321.71
Other Current Assets1.290.580.702.287.6813.54
Total Current Assets1,089.281,066.401,053.531,107.921,039.261,010.15
Net Property, Plant & Equipment1,708.961,700.051,689.381,648.841,562.961,518.63
Total Investments and Advances2.793.267.537.026.726.56
Intangible Assets104.11101.3399.72102.0098.1198.06
Deferred Tax Assets123.64122.98126.93121.99120.31117.09
Other Assets0.000.000.000.000.000.24
Total Assets3,030.102,994.012,977.082,987.772,836.462,760.05
Short Term Debt Incl. Current Port. of LT Debt142.71141.71143.74142.9897.4586.08
Accounts Payable277.61292.60293.07309.24247.22262.87
Income Tax Payable64.3654.1440.5626.3450.6359.56
Other Current Liabilities145.20172.67168.16150.80153.92156.82
Total Current Liabilities629.87661.13645.54629.36549.22565.33
Long Term Debt390.02364.76373.04407.72431.68401.01
Provision for Risks Charges8.539.0310.7011.6811.2711.22
Deferred Tax Liabilities16.2915.9216.8615.5715.5715.17
Other Liabilities161.28171.25167.12177.59139.91126.44
Total Liabilities1,205.991,222.081,213.261,241.931,147.651,119.17
Non-Equity Reserves13.570.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity1,810.511,771.891,763.781,745.801,688.761,640.83
Total Shareholders Equity1,810.511,771.891,763.781,745.801,688.761,640.83
Accumulated Minority Interest0.030.040.040.040.050.05
Total Equity1,810.541,771.931,763.821,745.841,688.811,640.88
Total Liabilities & Stockholders Equity3,030.102,994.012,977.082,987.772,836.462,760.05
Book Value Per Share6.636.496.466.396.196.01
Tangible Book Value Per Share6.256.126.106.025.835.65
Price to Book Ratio2.042.802.153.254.284.58
Return on Assets5.565.465.985.895.855.71
Return on Equity9.329.209.969.959.819.55
Return on Invested Capital2.191.251.532.571.991.65
Quick Ratio1.191.081.111.251.301.22
Current Ratio1.731.611.631.761.891.79

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income67.5844.0445.9175.9660.0247.17
Depreciation28.8527.9528.8426.9026.9326.12
Other Funds (Non Cash)-11.636.264.30-44.40-4.702.33
Funds from Operations84.8078.2479.0558.4782.2675.62
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-19.80-41.749.2750.17-21.98-16.63
Cash from Operating Activities65.0136.5088.32108.6360.2858.99
Capital Expenditures-40.06-75.91-82.73-109.25-61.19-74.12
Net Assets From Acquisitions2.51-2.510.000.000.000.00
Sale of Fixed Assets and Businesses1.990.290.450.260.300.48
Purchase or Sale of Investments-0.104.37-0.070.00-0.020.29
Purchase of Investments0.000.07-0.070.000.000.00
Sale Or Maturity of Investments-0.104.290.000.00-0.020.29
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-35.65-73.77-82.36-108.99-60.91-73.35
Cash Dividends Paid-16.960.000.000.07-17.220.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.000.000.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.000.000.000.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net30.66-0.17-27.2621.8641.5022.78
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities12.18-1.99-29.1719.9822.1821.14
Exchange Rate Effect0.820.991.560.400.70-3.48
Net Change in Cash42.35-38.27-21.6520.0322.253.30
Free Cash Flow28.21-30.0510.805.461.54-12.01
Price to Free Cash Flow---622.25--

Revenue breakdown

High Value Solutions2024: 456.97M 2025: 616.26M
Other Containment And Delivery Solutions2024: 553.30M 2025: 554.71M
Revenues From Engineering2024: 184.25M 2025: 167.05M
Asia Pacific2024: 104.12M 2025: 114.46M
Europe Middle East And Africa2024: 722.57M 2025: 778.65M
North America2024: 334.27M 2025: 408.38M
South America2024: 33.56M 2025: 36.54M
Biopharmaceutical And Diagnostic Solutions2024: 1.01B 2025: 1.17B
Engineering2024: 184.25M 2025: 167.05M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.81%0.9M48.9M391.57K
2026-10-151.97%1.0M48.9M375.14K
2026-09-302.23%1.1M48.9M370.57K
2026-09-152.42%1.2M48.9M378.11K
2026-08-312.26%1.1M49.7M397.09K
2026-08-142.07%1.0M49.7M364.37K
2026-07-311.82%0.9M49.7M365.99K
2026-07-151.94%1.0M49.7M412.07K
2026-06-301.90%0.9M49.7M480.88K
2026-06-151.83%0.9M49.7M516.94K
2026-05-292.03%1.0M49.7M543.95K
2026-05-152.04%1.0M49.7M597.17K
2026-04-301.78%0.9M49.7M666.40K
2026-04-152.12%1.1M49.7M746.71K
2026-03-312.33%1.2M49.7M692.94K
2026-03-133.04%1.5M49.7M621.77K
2026-02-273.10%1.5M49.7M572.12K
2026-02-133.87%1.9M49.7M538.11K
2026-01-304.53%2.3M49.7M438.48K
2026-01-154.75%2.4M49.7M302.92K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.5010.3013.000.0014.6500.000.000.991-0.0170.001
call5.008.2010.500.008.4940.000.000.936-0.1010.003
call7.505.708.000.006.1300.000.000.897-0.0970.004
call10.003.205.500.004.1470.000.000.840-0.0850.005
call12.500.752.401.151.85820.000.000.724-0.0640.007
call15.000.000.750.501.29744.000.000.412-0.0630.009
call17.500.000.750.002.0580.000.000.304-0.0890.008
call20.000.000.750.002.6320.000.000.260-0.1050.007
call22.500.000.750.003.0950.000.000.234-0.1170.007
call25.000.000.750.553.5467.000.000.217-0.1250.006
call30.000.000.750.004.1020.000.000.196-0.1400.006
put2.500.000.050.008.6670.000.00-0.029-0.0640.001
put5.000.000.750.006.5570.000.00-0.064-0.1010.003
put7.500.000.750.004.3550.000.00-0.103-0.0960.004
put10.000.000.750.002.8050.000.00-0.162-0.0840.005
put12.500.000.650.271.53069.000.00-0.276-0.0620.007
put15.000.451.851.301.44072.000.00-0.589-0.0620.009
put17.502.804.400.052.3573.000.00-0.696-0.0870.008
put20.005.406.900.002.9550.000.00-0.740-0.1030.007
put22.507.909.400.003.4340.000.00-0.766-0.1150.007
put25.0010.2012.100.004.1110.000.00-0.782-0.1230.006
put30.0015.3017.200.004.9120.000.00-0.804-0.1370.006

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-104Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-11-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-03SEC
2026-11-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-03SEC
2026-11-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-03SEC
2026-09-304Statement of changes in beneficial ownership of securities2026-09-28SEC
2026-09-14144Filing for proposed sale of securities under Rule 144.SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-13SCHEDULE 13GSEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-07SEC
2026-08-07144Filing for proposed sale of securities under Rule 144.SEC
2026-08-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-06SEC
2026-08-04SCHEDULE 13GSEC
2026-08-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-04SEC
2026-08-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-04SEC
2026-08-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-04SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-12SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-12SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-12SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-12SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-12SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-12SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-12SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-12SEC
2026-06-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-05SEC
2026-05-29SDSpecialized Disclosure ReportSEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-15SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-11326.75K100
2026-100000
2026-0900293.45K1
2026-0800166.28K3
2026-070000
2026-0600102.06K4
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Neuberger Berman Group LLC2.06%
Conestoga Capital Advisors, LLC2.05%
TimesSquare Capital Management, LLC1.19%
Van Berkom & Associates Inc.1.05%
Artisan Partners Limited Partnership0.95%
BAMCO INC /NY/0.91%
MORGAN STANLEY0.48%
CREDIT AGRICOLE S A0.48%
WELLINGTON MANAGEMENT GROUP LLP0.46%
Ranger Investment Management, L.P.0.35%

Funds

Fund% owned
Goldman Sachs Global Core Fixed Income Fund1.98%
CONESTOGA SMALL CAP FUND1.28%
Neuberger Genesis Fund1.12%
Carlyle Tactical Private Credit Fund0.83%
BARON DISCOVERY FUND0.62%
VANGUARD EMERGING MARKETS STOCK INDEX FUND0.48%
iShares Short Duration Bond Active ETF0.39%
EMERGING MARKETS CORE EQUITY 2 PORTFOLIO0.33%
Artisan Small Cap Fund0.31%
AMG TimesSquare Mid Cap Growth Fund0.24%

OakChart. STVN. Cached 15 minutes.